Follow
Dennie T. Frederick
Dennie T. Frederick
Massachusetts General Hospital
Verified email at mgh.harvard.edu
Title
Cited by
Cited by
Year
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ...
Science 352 (6282), 189-196, 2016
37132016
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
19392012
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ...
Cell 175 (4), 998-1013. e20, 2018
13202018
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ...
Science 357 (6356), 1156-1160, 2017
12582017
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ...
Cell 175 (4), 984-997. e24, 2018
9862018
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ...
Clinical cancer research 19 (5), 1225-1231, 2013
9782013
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF
R Haq, J Shoag, P Andreu-Perez, S Yokoyama, H Edelman, GC Rowe, ...
Cancer cell 23 (3), 302-315, 2013
8202013
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
M Sade-Feldman, YJ Jiao, JH Chen, MS Rooney, M Barzily-Rokni, ...
Nature communications 8 (1), 1136, 2017
7792017
Toward minimal residual disease-directed therapy in melanoma
F Rambow, A Rogiers, O Marin-Bejar, S Aibar, J Femel, M Dewaele, ...
Cell 174 (4), 843-855. e19, 2018
5562018
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
DJ Konieczkowski, CM Johannessen, O Abudayyeh, JW Kim, ZA Cooper, ...
Cancer discovery 4 (7), 816-827, 2014
5392014
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, ...
Nature medicine 24 (10), 1545-1549, 2018
5342018
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, ...
Cancer discovery 4 (1), 61-68, 2014
5172014
The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies
L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ...
Nature genetics 47 (3), 250-256, 2015
5122015
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ...
Nature communications 7 (1), 10582, 2016
4922016
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
CM Johannessen, LA Johnson, F Piccioni, A Townes, DT Frederick, ...
Nature 504 (7478), 138-142, 2013
4852013
Targeted next generation sequencing identifies markers of response to PD-1 blockade
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
4642016
Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo, DE Fisher, ...
Immunity 50 (6), 1498-1512. e5, 2019
4472019
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ...
Clinical cancer research 19 (2), 393-403, 2013
3962013
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ...
Nature 532 (7598), 250-254, 2016
3532016
Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ...
Clinical Cancer Research 18 (19), 5329-5340, 2012
3202012
The system can't perform the operation now. Try again later.
Articles 1–20